A new technology allows scientists to map the DNA-binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by Weill Cornell Medicine and the New York Genome Center.
A clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
The Cornell Duffield College of Engineering will accelerate its Engineering Innovations in Medicine initiative, which aims to revolutionize how biomedical data is acquired, computed, and translated into impact.
Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults.
The new freezing method – 30 times faster than current protocols – could be used to improve assisted reproduction in humans or animals or to conserve biodiversity.
